Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

NCT06747507 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

392

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Dolutegravir Pill
DRUG: Darunavir+Ritonavir

Sponsor

University of Nairobi

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]